Pediatr. praxi. 2011;12(4):242-246

Clinical use of specific antifungals

PharmDr.Petr Horák
Nemocniční lékárna FN Motol a Katedra lékárenství IPVZ, Praha

The incidence of systemic fungal infections especially has been growing in last decades. It is related to the expansion of HIV/AIDS pandemic

and also to the development of therapy of many diseases that affect immunity. It has resulted in the development of new drugs

and new therapeutic classes, or changes in the administration and indications of formerly known drugs. Moreover, new therapeutic

approaches have also been employed in the therapy of topical mycoses, and this article is devoted to them, too.

Keywords: antifungals, systemic mycosis, topical mycosis, molds, candidas

Published: September 2, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horák P. Clinical use of specific antifungals. Pediatr. praxi. 2011;12(4):242-246.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Borovanský A. Farmaceutická chemie VI. Antiinfektiva - Antimykotika, antivirotika. Farmaceutická fakulta VŠVF, Brno 1993: 15-41.
    2. Lexi-Drugs. In Lexi-Complete iPhone edition, [cit. 20. 4. 2010].
    3. Databáze registrovaných léčivých přípravků a PZLÚ SÚKL. Dostupné na http://www.sukl.cz/modules/medication/ search.php [cit. 20. 4. 2010].
    4. Haber J. Amphotericinum B. Remedia 1994; 4(5): 274-283.
    5. Bing CM. Extended Stability for Parenteral Drugs. American Society of Health-System Pharmacists, 2005: 230.
    6. Sklenář Z, Hašek J. Nové léčivé přípravky v magistraliter receptuře I. - Nystatin. Prakt. lékáren. 2010; 6(1): 30-35.
    7. Helms RA (ed.). Textbook of therapeutics, 8. vyd., Lippincott Williams & Wilkins, 2006: 2172-2193.
    8. Automatizovaný informační systém léčivých přípravků. Mikroverze ČR, verze 2010.2, [cit. 20. 4. 2010].
    9. Sweetman SC (ed.). Martindale: The Complete Drug Reference. 36th Edition. Pharmaceutical Press, 2009: 3694.
    10. McEvoy GK (ed.). AHFS Drug Information 2007. American Society of Health-System Pharmacists. 2007: 3824.
    11. Harrison's Practice. In Lexi-Complete iPhone edition, [cit. 20. 4. 2010].
    12. Zazula R, Schindler I, Spálený A, et al. Současný pohled na mykotické plicní infekce. Interní Med. 2005; (7-8): 349-353.
    13. Petrikkos G, Skiada A. Recent advances in antifungal chemotherapy. International Journal of Antimicrobial Agents 2007; 30: 108-117. Go to original source... Go to PubMed...
    14. Skořepová M. Léčba kožních mykóz. Practicus 2008; 4: 12-16.
    15. DiPiro JT (ed.). Pharmacotherapy. A Pathophysiological Approach. 6th Edition. McGraw Hill, 2005: 2802.
    16. Armour D, Cairns C (ed.). Medicines in the Elderly. Pharmaceutical Press, 2002: 428.
    17. Sobel JD, Faro S, Force RW. Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998; 178(2): 203-211. Go to original source... Go to PubMed...
    18. Shahid Z, Sobel JD. Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagnostic Microbiology and Infectious Disease 2009; 64: 354-356. Go to original source... Go to PubMed...
    19. Kaufman D. Neonatal Candidiasis: Clinical Manifestations, Management, and Prevention Strategies. Journal of Pediatrics 2010; 156(4) (Suppl 2): S53-S68. Go to original source...
    20. Roilides E. Invasive candidiasis in neonates and children, Early Hum Dev (2011), doi: 10.1016/j.earlhumdev.2011.01.017 (v tisku). Go to original source... Go to PubMed...
    21. Healy CM, Baker CJ, Zaccaria E, et al. Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J Pediatr 2005; 147(2): 166-171. Go to original source... Go to PubMed...
    22. Arrieta AC, Shea K, Dhar V, et al. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study. Clin Ther, 2010; 32(2): 265-271. Go to original source... Go to PubMed...
    23. Kaufman D. Strategies for Prevention of Neonatal Invasive Candidiasis. Seminars in Perinatology 2003; 27(5): 414-424. Go to original source... Go to PubMed...
    24. McDonell M. Fungal infections in the newborn. Semi Neonatol, 1996; 1: 141-145. Go to original source...
    25. Wiley JM. Fungal Infections in Pediatric Immunocompromised Patients: Epidemiology, Principles of Treatment, and Promising Antifungal Agents. Journal of Pediatrics 2010; 156(4): 74-83. Go to original source...
    26. Watt K, Benjamin DK. Pharmacokinetics of antifungal agents in children. Early Hum Dev (2011), doi: 10.1016/j.earlhumdev.2011.01.014 (v tisku). Go to original source... Go to PubMed...
    27. Ráčil Z, Kocmanová I, Mayer J. Micafungin - nový echinokandin. Farmakoterapie 2009; 2: 165-172.
    28. Castagnola E, Faraci M, Fioredda, F. Invasive mould infections in newborns and children. Early Hum Dev (2011), doi: 10.1016/j.earlhumdev.2011.01.015 (v tisku). Go to original source... Go to PubMed...
    29. Infectious Diseases. In Lexi-Complete iPhone edition [cit. 20. 4. 2010].
    30. Thia LP, Balfour Lynn IM. Diagnosing allergic bronchopulmonary aspergillosis in children with cystic fibrosis. Paediatr Respir Rev 2009; 10(1): 37-42. Go to original source... Go to PubMed...
    31. de Almeida MB, Bussamra MH, Rodrigues JC. Allergic bronchopulmonary aspergillosis in paediatric cystic fibrosis patients. Paediatr Respir Rev, 2006; 7(1): 67-72. Go to original source... Go to PubMed...
    32. Hatziagorou E, Walsh TJ, Tsanakas JN. Aspergillus and the paediatric lung. Paediatr Respir Rev, 2009; 10(4): 178-185. Go to original source... Go to PubMed...
    33. Haber J. Mallátová N. Voriconazol. Farmakoterapie 2005; 5: 443-462.
    34. Haber J, Mallátová N. Posakonazol. Remedia 2007; 17(1): 50-59.
    35. Haber J, Mallátová N. Lipidový komplex amphotericinu B - jeho role mezi ostatními antimykotiky v léčbě invazivní kandidózy. Analýza klinických studií. Remedia 2007; 17(5): 511-523.
    36. Ramdial PK, Sing Y, Deonarain J, et al. Pediatric Renal Cryptococcosis: Novel Manifestations in the Acquired Immunodeficiency Syndrome Era. Int J Surg Pathol. (2010). Go to original source... Go to PubMed...
    37. Natukunda E, Musiime V, Ssali F, et al. A Case of Cryptococcal Lymphadenitis in an HIV-Infected Child. AIDS Res Hum Retroviruses 2010; 26: 1-4. Go to original source... Go to PubMed...
    38. Mišunová L. Mykotické infekce u HIV pozitivních pacientů. Alergie 2009; 2: 141-149.
    39. Carmona EM, Limper AH. Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis 2011; 5(1): 41-59. Go to original source... Go to PubMed...
    40. Kuklová I. Mykózy kůže a nehtů. Med. pro praxi 2006; 3: 129-131.
    41. Ginter-Hanselmayer G, Seebacher C. Treatment of tinea capitis - a critical appraisal. J Dtsch Dermatol Ges, 2011; 9(2): 109-114. Go to original source... Go to PubMed...
    42. Skořepová M. Dermatofytózy u dětí. Pediatr. praxi 2008; 9(3): 178.

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.